Human immunodeficiency virus type 1 polymerase-derived cytotoxic T lymphocyte epitope (HIV-1 Pol CTL epitope)

HIV-1 Pol-derived CTL epitopes are short peptide sequences, typically 8 to 11 amino acids in length, that originate from the highly conserved polymerase (Pol) polyprotein of the Human Immunodeficiency Virus type 1 (UniProtKB - P03366). This polyprotein is essential for viral replication, as it is processed into the viral protease, reverse transcriptase, and integrase enzymes. These epitopes are presented on the surface of infected cells by Major Histocompatibility Complex (MHC) Class I molecules, where they are recognized by the T-cell receptors (TCRs) of CD8+ cytotoxic T lymphocytes (CTLs) (Goulder & Watkins, 2004). Upon recognition, CTLs induce apoptosis in the infected cell through the release of perforins and granzymes and secrete antiviral cytokines such as interferon-gamma (Walker et al., 1987). Because the Pol region is functionally constrained, mutations within these epitopes often lead to a significant reduction in viral fitness, making them high-priority targets for therapeutic vaccines and TCR-engineered T-cell therapies (Los Alamos HIV Database). Clinical development focuses on identifying immunodominant epitopes that can elicit a robust and broad immune response to control the viral reservoir in patients (Hanke et al., 1999). These targets are particularly valuable because they allow the immune system to recognize and eliminate cells harboring the virus even during periods of low replication.

Other names

HIV-1 Pol peptideHIV-1 Pol antigenCD8+ T-cell epitope of HIV-1 PolPol-derived epitope

Presentation of viral peptides by MHC Class I molecules to CD8+ T cells, inducing targeted lysis of HIV-infected cells and cytokine production.